Sydney Lupkin

So there is a lot of excitement around a new pill form of the drug.

We're going to talk about two types of these pills.

The first is a Wagobe pill that's expected to win FDA approval by the end of the year.

And then there's another kind of obesity pill that could be right behind it.

And what FDA approval would mean for affordability and access.

GLP-1s.

So, yeah, I talked about this with Andrea Trena.

Her background is in clinical pharmacy, and now she's an obesity director at Novo Nordisk.

That's the company that makes Ozempic and Wegovy.

And Emily, at my request, she went full frizzle during our interview.

100%.

Here is her primer on GLP-1s.

And GLP-1, by the way, is a hormone your body naturally makes.

It stands for glucagon-like peptide 1.

It lasts much longer.

When Novo Nordisk made its medication version of GLP-1, the company tweaked it.

The active ingredient in both blockbuster drugs, Ozempic and Magovi, is called semaglutide.

Andrea explained how they made it.

Right.

By the way, there are four different blockbuster injectables.